PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective

Overview

Journal AAPS J

Specialty Pharmacology

Date 2019 Jan 24

PMID 30673891

Citations 22

Authors

Cordula Stillhart

Xavier Pepin

Christophe Tistaert

David Good

An Van den Bergh

Neil Parrott

Filippos Kesisoglou

Affiliations

Soon will be listed here.

Abstract

The establishment of an in vitro-in vivo correlation (IVIVC) is considered the gold standard to establish in vivo relevance of a dissolution method and to utilize dissolution data in the context of regulatory bioequivalence questions, including the development of dissolution specifications. However, several recent publications, including industry surveys and reviews from regulatory agencies, have indicated a low success rate for IVIVCs, especially for immediate-release formulations. In recent years, the use of physiologically based pharmacokinetics (PBPK) and absorption modeling, as a tool to facilitate formulation development, has been attracting increased attention. This manuscript provides an industry perspective on the current challenges with establishing IVIVCs and the potential PBPK and absorption modeling offer to increase their impact. Case studies across both immediate-release and extended-release formulations from five pharmaceutical companies are utilized to demonstrate how physiologically based IVIVC (PB-IVIVC) may facilitate drug product understanding and to inform bioequivalence assessment and clinically relevant specifications. Finally, PB-IVIVC best practices and a strategy for model development and application are proposed.

Citing Articles

Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta-9-Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes.

Qian L, Zhang T, Dinh J, Paine M, Zhou Z Clin Transl Sci. 2025; 18(1):e70119.

PMID: 39748462 PMC: 11695271. DOI: 10.1111/cts.70119.

Physiologically Based Pharmacokinetic Modeling to Assess Ritonavir-Digoxin Interactions and Recommendations for Co-Administration Regimens.

Chen Y, Shao W, Wang X, Geng K, Wang W, Li Y Pharm Res. 2024; 41(11):2199-2212.

PMID: 39557814 DOI: 10.1007/s11095-024-03789-w.

Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.

Wang M, Heimbach T, Zhu W, Wu D, Reuter K, Kesisoglou F AAPS J. 2024; 26(4):69.

PMID: 38862807 DOI: 10.1208/s12248-024-00938-2.

In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug.

Gonzalez-Alvarez I, Ruiz-Picazo A, Selles-Talavera R, Figueroa-Campos A, Merino V, Bermejo M Pharmaceutics. 2024; 16(3).

PMID: 38543284 PMC: 10974868. DOI: 10.3390/pharmaceutics16030390.

Model-Informed Drug Development: In Silico Assessment of Drug Bioperformance following Oral and Percutaneous Administration.

Djuris J, Cvijic S, Djekic L Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399392 PMC: 10892858. DOI: 10.3390/ph17020177.

References

Kakhi M, Suarez-Sharp S, Shepard T, Chittenden J . Application of an NLME-Stochastic Deconvolution Approach to Level A IVIVC Modeling. J Pharm Sci. 2017; 106(7):1905-1916. DOI: 10.1016/j.xphs.2017.03.015. View

Loo J, RIEGELMAN S . New method for calculating the intrinsic absorption rate of drugs. J Pharm Sci. 1968; 57(6):918-28. DOI: 10.1002/jps.2600570602. View

Suarez-Sharp S, Li M, Duan J, Shah H, Seo P . Regulatory Experience with In Vivo In Vitro Correlations (IVIVC) in New Drug Applications. AAPS J. 2016; 18(6):1379-1390. DOI: 10.1208/s12248-016-9966-2. View

Pathak S, Ruff A, Kostewicz E, Patel N, Turner D, Jamei M . Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. Mol Pharm. 2017; 14(12):4305-4320. DOI: 10.1021/acs.molpharmaceut.7b00406. View

Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S . Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach. Clin Pharmacol Ther. 2015; 99(2):224-34. DOI: 10.1002/cpt.206. View

Andreas C, Pepin X, Markopoulos C, Vertzoni M, Reppas C, Dressman J . Mechanistic investigation of the negative food effect of modified release zolpidem. Eur J Pharm Sci. 2017; 102:284-298. DOI: 10.1016/j.ejps.2017.03.011. View

Grady H, Elder D, Webster G, Mao Y, Lin Y, Flanagan T . Industry's View on Using Quality Control, Biorelevant, and Clinically Relevant Dissolution Tests for Pharmaceutical Development, Registration, and Commercialization. J Pharm Sci. 2017; 107(1):34-41. DOI: 10.1016/j.xphs.2017.10.019. View

Stillhart C, Parrott N, Lindenberg M, Chalus P, Bentley D, Szepes A . Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing. AAPS J. 2017; 19(3):827-836. DOI: 10.1208/s12248-017-0060-1. View

Cook J . Development strategies for IVIVC in an industrial environment. Biopharm Drug Dispos. 2012; 33(7):349-53. DOI: 10.1002/bdd.1791. View

10.

Colon-Useche S, Gonzalez-Alvarez I, Mangas-Sanjuan V, Gonzalez-Alvarez M, Pastoriza P, Molina-Martinez I . Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug. Mol Pharm. 2015; 12(9):3167-74. DOI: 10.1021/acs.molpharmaceut.5b00076. View

11.

Kesisoglou F, Xia B, Agrawal N . Comparison of Deconvolution-Based and Absorption Modeling IVIVC for Extended Release Formulations of a BCS III Drug Development Candidate. AAPS J. 2015; 17(6):1492-500. PMC: 4627461. DOI: 10.1208/s12248-015-9816-7. View

12.

Kesisoglou F . The Role of Physiologically Based Oral Absorption Modelling in Formulation Development Under a Quality by Design Paradigm. J Pharm Sci. 2016; 106(4):944-949. DOI: 10.1016/j.xphs.2016.11.022. View

13.

Nguyen M, Flanagan T, Brewster M, Kesisoglou F, Beato S, Biewenga J . A survey on IVIVC/IVIVR development in the pharmaceutical industry - Past experience and current perspectives. Eur J Pharm Sci. 2017; 102:1-13. DOI: 10.1016/j.ejps.2017.02.029. View

14.

Cvijic S, Parojcic J, Langguth P . Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro experimental simulation and computational verification. Eur J Pharm Sci. 2014; 61:40-53. DOI: 10.1016/j.ejps.2014.04.008. View

15.

Chan K, Langenbucher F, Gibaldi M . Evaluation of in vivo drug release by numerical deconvolution using oral solution data as weighting function. J Pharm Sci. 1987; 76(6):446-50. DOI: 10.1002/jps.2600760607. View

16.

Wagner J . Method for estimating rate constants for absorption, metabolism, and elimination from urinary excretion data. J Pharm Sci. 1967; 56(4):489-94. DOI: 10.1002/jps.2600560413. View

17.

Mitra A, Kesisoglou F, Dogterom P . Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets. AAPS PharmSciTech. 2014; 16(1):76-84. PMC: 4309824. DOI: 10.1208/s12249-014-0194-8. View

18.

Kaur P, Jiang X, Duan J, Stier E . Applications of In Vitro-In Vivo Correlations in Generic Drug Development: Case Studies. AAPS J. 2015; 17(4):1035-9. PMC: 4476988. DOI: 10.1208/s12248-015-9765-1. View

19.

Jermain S, Brough C, Williams 3rd R . Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update. Int J Pharm. 2017; 535(1-2):379-392. DOI: 10.1016/j.ijpharm.2017.10.051. View

20.

Margolskee A, Darwich A, Galetin A, Rostami-Hodjegan A, Aarons L . Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions. AAPS J. 2015; 18(2):321-32. PMC: 4779109. DOI: 10.1208/s12248-015-9849-y. View